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Abstract. Two processes govern the generation oJ
thrombin: proteolytic proenz\me activation and hetero-
geneous biocatalysis. The main reaction sequence of
proenzyme activation is F VII ---> F X'--> F II . And there
is a reinforcement loop constituted b1, the reactions
F VII ---> F IX ---> F X. All activations in this central
triangle of blood coagulation require a protein cofactor
and phospholipid. The protein cofactors from the
plasma (F V and F VIII) have to be activated blt thrombin
in order to function. This means that thrombin
acts in a positive feedback loop. This is the more
important because thrombin will cause platelets that
stick to collagen to present their procoagulant phospho-
lipids at the outside of their plasma membrane. The two
most probable sites of action of heparin are: inhibition
of thrombin and frustration of the feedback loops andlor
inhibition of factor X,,.
Le sch6ma de la coagulation 1984
R6sum6. 2 processus servent de base d la formation de
la thrombine : l'activation prot4oll:tique des proenzvmes
et la biocatalyse hdtdrogine. La siquence principale
d'activation des proenzymes est F. VII ---> F. X ---> F. II.
Il existe une boucle de renforcement sous la forme des
riactions F. Vil ---> F. IX ---> F. X. Dans ce triangle
central de la coagulation du sang toutes les activations
requiirent des cofacteurs protiiques et des phospho-
lipides. Les cofacteurs protdiques du plasma (F. V et
F. VIil) requiirent pour fonctionner I'activation par la
thrombine qui ainsi agit dans une boucle positive de
rdtroaction. Ceci est d'autant plus important que la
thrombine agit au niveau des plaquettes pour leur
permettre d'adhdrer au collagine en prdsentant leurs
phospholipides coagulants d la partie externe de Ia
membrane plasmique. Les 2 plus probables sites
-/C*zgg*,%.**
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d'action de I'hiparine sont : I'inhibition de la thrombine
et I'inhibition des boucles de rdtroaction etlou I'inhibi-
tion du facteur Xn.
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It is a tradition among specialists in the field of blood
coagulation to present their knowledge and speculation
in the form of complicated diagrams. This may be partly
due to the fact that coagulation is a relatively compli-
cated process, partly however these intricate schemes
have a charm of their own. On the other hand there is
also a certain challenge in trying to present and intricate
mechanism in a simple way. Therefore we will here try
our hand at a simple representation of the mechanism of
thrombin formation, perhaps at the cost of oversimplifi-
cation.
Elementary processes
Two elementary processes suffice to describe the
mechanism of thrombin formation.
Activation
Activation indicates the conversion of a protein from an
inactive into an active form by limited proteolysis. For
proteolytic enzymes, especially the serine proteases uch
as trypsin, this process has been extensively studied in
classical biochemistry. It is interesting to note however
that the process as such was probably first discovered in
the field of blood coagulation when Pekelharing disco-
vered prothrombin []. In blood coagulation activation
often is a proenzyme-enzyme conversion. This is theOffprint requests to : HC Hemker
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case with the factors II, VII, IX, X, XI, XII and
prekallikrein. In the case of the factors V and VIII
however a protein that has no enzymatic action of its
own but that acts as a cofactor to a serine protease is the
product of limited proteolysis [2].
In the following we will adopt a short hand notation
for proteolytic activation. X + II means that activated
factor X exerts its proteolytic action upon factor II
(prothrombin) so as to activate it. It is not to be
confused with the usual chemical convention which
would indicate that X is converted into II.
Heterogeneous biocatalysis
The main reactions that lead to thrombin formation do
not take place between molecules in free solution, but
occur when the reaction partners are adsorbed at an
interface. Apart from the activating enzyme and the
substrate that is to be activated there is usually a third
reaction partner, the protein cofactor that is also
adsorbed at the interface and that helps in making the
reaction more efficient. Let us take prothrombinase as
an example: the activation of prothrombin is brought
about by a complex of the factors Xu and Vu, adsorbed
at a phospholipid surface while the prothrombin itself is
also adsorbed to the surface [2].
The proteolytic reaction chain
The core of the coagulation process is a chain of
interactions between proteolytic enzymes and proen-
zymes. There is good reason to assume that the main
trigger enzyme of blood coagulation is factor VII [3].
The most important reaction sequence of blood coagula-
tion is then given by:
VII --+ X -+ lI
As it has been demonstrated that factor Xo can activate
factor VlI, [4] the first activation step is reciprocal.
V I I s X - + l I
Factor VII can also activate factor lX [5], that in its turn
activates factor X as well as factor VII t6l. This leads to
the following scheme:
VII
/ \ \/ /  \  \
i l \ \
i l \
i l \f i { \
lx+x+II
Apart from factor VII and tissue factor there is an
alternative way of activating factor IX via the contact
Fig. 1. The proteases of blood coagulation. The roman numerals
indicate the respective coagulation factors. PK : prekallikrein. The
arrows indicate activation by limited proteolysis (c) copyright Coen
Hemker
activation mechanism. This mechanism starts via the
mutual activation of prekallikrein and factor XII and
then continues by the activation of factor Xl [7].
PK ss XII -+ Xl
Inclusion of this activation pathway completes the
proteolytic reaction chain. Also the activation of factor
VII by factor XII can be taken into account t8l (Fig. 1).
Heterogeneous catalysis
The reactions in the VII -+ IX -+ X domain occur at a
phospholipid-solute interphase. Negatively charged
phospholipids (especially phosphatidyl serine, PS) are
essential. Under physiological circumstances the cell
membrane of triggered blood platelets and the phospho-
lipids from the inside of wounded cells serve as the
necessary surface. Cell membranes of intact cells and
non triggered platelets do not provide the necessary
phospholipids [9]. Each of the three activation reactions
under discussion has its specific non enzyme protein
cofactor [2].
1) Factor VII., activating factor X and factor IX needs
the protein component of tissue factor (TF).
2) Factor IXu activating factor X needs activated factor
vrrr u0j.
3) Factor Xu acting upon prothrombin (factor II) needs
activated factor v Il l ].
The contact activation reactions take place at negatively
charged surfaces such as kaolin, glass or sulphatide
micelles, phospholipids do not play a role here [12].
High molecular weight kininogen acts as a non enzyma-
tic protein cofactor [13]. This completes our scheme of
the reaction mechanism of prothrombin activation
(Fie. 2).
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Fig. 2. A clotting scheme for 1984. In addition to fig. I the non
enzymatic cofactors and the surfaces at which the reaction takes place
are indicated. N.S. : negatively charge surface. HMWK : High
Molecular Weight Kininogen. TF = Tissue Factor. @ copyright Coen
Hemker.
Triggering mechanisms
A wounded cell will provide tissue thromboplastin.
Tissue thromboplastin consists of a non protein cofactor
for factor VII firmly attached to membrane particles that
provide a suitable phospholipid surface for the adsorb-
tion of factors VII^ and X [14].
It is interesting to note that the proenzyme factor VII
has a measurable protgolytic activity even before being
converted into factor VII" [15]. This means that the
adsorbtion of circulating factor VII into the tissue
thromboplastin shed out by wounded wells will form a
complex capable of activating factor X. Factor Xu will
then convert factor VII into factor VII' and thus the
coagulation mechanism is started.
Factor Xu adsorbed onto phospholipid will be able to
produce thrombin at a low rate even in the absence of
factor Vu. Once the first molecules of thrombin have
been formed a set of positive feedback reactions will set
in. They will be discussed in detail below but it is
important to note that the explosive triggering of
thrombin formation in wounded tissue can be explained
by these feedback reactions.
If blood from an ideal venipuncture is brought into
contact with a foreign surface such as glass, coagulation
starts rather by the mutual activation of prekallikrein and
factor XII then by activation of factor VIl. One has to
assume a minute activity of at least either factor XII or
prekallikrein in order to explain that the process gets
started. Apart from glass and other surfaces rare in the
human body a few other mechanisms are claimed to be
able to activate the contact factors, such as bacterial
lipopolysaccharides, structural elements found in suben-
dothelium of blood vessels [6] and according to Walsh,
TFTtr
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platelets triggered by either ADP or collagen [17]. The
triggering by contact activation is traditionaly known as
the intrinsic pathway, whereas the extrinsic pathway is
the one triggered by the thromboplastin from wounded
tissue.
The importance of contact activation may have been
overestimated in the early literature because it was
recognised that the antihaemophilic factors (factors VIII
and IX), the importance of which cannot be denied,
have a place in the intrinsic pathway. It was observed
relatively late that factor VII activates factor IX so that
the antihaemophilic factors also form a reinforcement
loop in the extrinsic pathway [18]. The importance of
this fact, discovered as early as 1965 by Josso, may
have escaped attention because in vitro one works either
in complete absence of TF (recalcification time, APTT),
so that clotting proceeds via a factor VII independent
pathway or in the presence of an excess of tissue
thromboplastin (Quick test and its modifications). Under
these two circumstances the reinforcement loop is not
important because the pathway VII -+ IX -+ X shows its
importance only in the presence of small amounts of TF.
When factor VII cannot immediately activate large
amounts of factor X, the growing amount of factor lXu
becomes an important second factor X activator in the
course of the reaction process [3]. In this respect it may
be interesting to note that the bleeds of haemophiliacs
are as a rule more important in thromboplastin poor
tissues such as joints and muscle then in thromboplastin
rich ones such as brain and lune.
Feedback mechanisms bv thrombin
Probably blood coagulation, i.e. the formation of a
fibrin clot, is by no means the most important action of
thrombin in haemostasis. The fact that afibrinogenaemia
does not automatically lead to a serious bleeding
condition indicates this. As the important role of
thrombocytes in haemostatic and thrombotic processes
has become more and more recognised in the last
decades one would rather think that the interaction of
thrombin and platelets is the key reaction of haemostas-
is. Now this is not a one-way reaction. Thrombin is
known to be the most potent platelet activator but also
activated blood platelets obtain important procoagulant
properties. ln the first place thrombin induces in
platelets the release reaction by which factor V becomes
available [19] . Because the plasma concentration of
factor V is -25 nM whereas that of its partner, factor X
is -180 nM the contribution of platelet factor V, which
after complete release in normal blood constitutes
another 25 nM, is not negligible. lt is hard to tell what
the importance is under conditions where the proportions
of platelets to plasma shifts in favour of the platelets, as
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in the case in the haemostatic plug and thrombus.
Anyhow the factor V contribution to the platelets will
tend to become more important under these conditions.
In the second place low concentrations of thrombin
(-1 nM, i.e. <1 Vo of the thrombin potentially gener-
ated in blood) will induce the so called flip flop reaction
in platelets that are in contact with collagen [9]. This
means that the procoagulant, negatively charged, phos-
pholipids that in the resting platelet are to be found
almost uniquely at the inner layer of the cell membrane
are moved to the outer layer by a transbilayer movement
[20]. Large concentration of thrombin alone will also
cause some flip flop, whereas in platelet ghosts and
debris of course the inside of the membrane is randomly
accessible from the outside. Thrombin also makes
platelets aggregate and the aggregate is reinforced by
fibrin formation.
It is clear that coagulation and platelet reactions are
not independent or parallel processes but are tightly
interwoven in a positive feedback mechanism that will
lead to an important amplification of both processes.
Two more positive feedback processes take place in
the thrombin generation process. Thrombin converts
factor V into a form that is able to be active as a
cofactor of factor Xu and it likewise activates factor
Vl[-C, the cofactor of factor IXu.
Apart from positive feedback there are also negative
feedback loops involved in thrombin generation. It is
interesting to see that these are separated from the
positive effects in time and/or in space. By its reaction
with thrombomodulin, a protein bound to the endothelial
surface, i.e. outside the area of the wound, thrombin
will become a potent activator of protein C I2I).
Activated protein C breaks down activated factor V and
probably also factor VIII 122). Activated factor VIII,
when not present in the phospholipid-IX"-Vlllu complex
is unstable anyhow, be it that its breakdown is about
tenfold slower than its activation. Thrombin can also
attack prothrombin so as to make it a bad substrate for
prothrombinase (phospholipid-Xa-Va) and the activation
peptides of prothrombin, i. e. that part of the molecule that
does not constitute thrombin, is an inhibitor of prothrombi-
nase (product inhibition) [23].
Mode of action of oral anticoagulants
Oral anticoagulants inhibit a step in the synthesis of the
vitamin K dependent coagulation factors, so that the
y-carboxyglutamic acids that normally occur in these
factors are not present [24]. Because of this deficiency
the factors cannot adsorb onto phospholipids and hence
cannot take part in the activating complexes either as
enzyme or as substrate. This causes a decrease of the
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function of the VII-IX-X triangle and so thrombin
formation is inhibited.
Because of the many feedback reactions triggered by
small amounts of thrombin it is not surprising that there
is no linear relationship between the decrease of the
prothrombin level and the antithrombotic action caused
by oral anticoagulation. Anticoagulation that causes a
level of vitamin K dependent coagulation factors that is
under 2O7o of the normal level is necessary to obtain a
manifest antithrombotic effect in the arteries. Bleeding
will start to be a problem below 57o-l0%o. It is not as yet
clear how the decrease of the anticoagulant protein C
caused by oral anticoagulation influences the thrombotic
tendency.
Mode of action of heparin
The heparin-antithrombin III complex is an efficient
scavenger of thrombin and the factors Xu, IXu, XIu and
XII.. It is reported to be less active against kallikrein
and inactive against factor VII. [251. h is important to
note however that this pertains to the activated factors in
free solution. It has been shown that as soon as factor Xu
takes part in the prothrombinase complex it is no longer
subject to the inhibitory action of antithrombin III with
or without heparin [26]. This raises the interesting
question of why and how heparin influences haemostasis
and thrombosis in vivo. One possibility is that the action
against free thrombin is important in an early stage of
blood coagulation because the feedback mechanisms via
thrombin are frustrated. Another possibility is that
soluble factor Xu is attacked and that thus bound factor
Xu is withdrawn from the prothrombinase complex. This
seems less likely in view of the tight binding of factor
Xu there [21).It remains possible however that factor Xu
is accessible to inhibitory action when it passes from its
activating enzymes (i.e. VII"-TF and IX^-VIII.PL) to the
prothrombinase complex. We plan to study this problem
in the near future.
Still another possibility is that the direct interaction
of heparin with thrombin elicits its action on one or
more high molecular weight substrates uch as factors V
and VIII or the platelet. The recent development of pure
fractions from natural heparin and of synthetic heparins
of precisely known composition [28] open the possibility
of obtaining materials that selectively show one or more
of the known actions of natural heparin. In this way
heparin fractions that do not induce an increased
antithrombin activity in antithrombin III have been
found. Also a dissociation of the inhibitory capacity of
heparin towards the different functions of thrombin has
been observed t29). Comparison of the detailed mechan-
ism of action of specific purified heparins with their
antithrombotic and antihaemostatic properties opens up
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the fascinating possibility of finding what processes in
the thrombin generating mechanisms play the key role in
haemostasis or thrombosis. In this way one hopes to find
modes of inhibition that selectively act on thrombus
formation but leave haemostasis largely unaffected. This
must be considered a real possibility because, no matter
how intimately connected these processes are, they are
different. In fact the problem is comparable to finding
antibiotics that effect the protein synthesis of bacteria
but not that of human cells or to the finding of
chemotherapeutics that affect cancer cells only.
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